Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

ImmunoGen Initiates Phase Evaluation of IMGN901

By Drug Discovery Trends Editor | April 2, 2012

ImmunoGen Inc. has initiated Phase 2 testing of its IMGN901 product candidate for first-line treatment of small cell lung cancer (SCLC). The assessment, known as the NORTH trial, is designed to evaluate whether the addition of IMGN901 to standard first-line care for SCLC meaningfully impacts duration of progression-free survival (PFS). With SCLC, the efficacy of first-line treatment is considered to be particularly important due to the low likelihood of obtaining a marked, sustained response with any subsequent treatment.


“Our experience with IMGN901 to date—preclinical and clinical—supports Phase 2 evaluation of IMGN901 for first-line use in SCLC,” commented James O’Leary, MD, vice president and chief medical officer. “SCLC almost universally expresses the CD56 antigen targeted by IMGN901, and there is a clear need for more effective treatments for this cancer. We have a number of clinical sites already open for patient enrollment, with many additional sites on track to open over the next month.”


The trial is designed to include 120 patients (80 in the IMGN901 plus C/E arm and 40 in the C/E alone arm). It utilizes a Simon Two-Stage Design. Once the specified number of patients has been enrolled (39 in the IMGN901 plus C/E arm; 20 in the C/E alone arm), these patient cohorts will be followed to establish whether the treatment arm that includes IMGN901 met the pre-defined hurdle for success, which is based on PFS at 6 months compared to historic controls. Success on this interim analysis will serve as a basis for certain development decisions by the company.


The primary endpoint of the trial is PFS. Secondary endpoints include PFS at 6 months, overall survival at 12 months, time to progression, overall survival, and overall response rate. The trial is designed to compare these findings to historic controls, with its control arm serving to verify consistency with historical results.


IMGN901 is designed to target and kill CD56-expressing cancer cells. It is wholly owned by ImmunoGen and consists of the Company’s CD56-targeting antibody with its proprietary DM1 cancer-cell killing agent attached using one of its engineered linkers. IMGN901 has been granted orphan drug designation for SCLC in the United States and in Europe.


Release date: March 30, 2012
Source: ImmunoGen, Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE